Reports Q3 revenue $14.46B, consensus $14.28B. “We delivered another quarter of strong commercial execution and significant pipeline progress,” said Robert Michael, chief executive officer, AbbVie (ABBV). “Based upon the momentum of AbbVie’s business and our confidence in the long-term growth outlook, we are once again raising our full-year guidance and are increasing our quarterly dividend.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie small cell lung cancer treatment granted FDA orphan designation
- Notable companies reporting before tomorrow’s open
- M&A News: AbbVie (NYSE:ABBV) Will Acquire Aliada Therapeutics for $1.4B
- AbbVie to acquire Aliada Therapeutics for $1.4B in cash
- Options Volatility and Implied Earnings Moves This Week, October 28 – November 01, 2024